Glycosylated Hemoglobin as a Predictor for Effectiveness of Sildenafil Citrate for Diabetic Patients with Erectile Dysfunction.
- Author:
Dong Yup HAN
1
;
Hee Kwan RIM
;
Ill Young SEO
;
Joung Sik RIM
Author Information
1. Department of Urology, Wonkwang University School of Medicine, Iksan, Korea.
- Publication Type:Original Article
- Keywords:
Diabetes;
Erectile dysfunction;
Sildenafil citrate;
Glycosylated hemoglobin
- MeSH:
Body Mass Index;
Citric Acid*;
Diabetes Complications;
Diabetic Neuropathies;
Diabetic Retinopathy;
Erectile Dysfunction*;
Hemoglobin A, Glycosylated*;
Humans;
Male;
Smoke;
Smoking;
Sildenafil Citrate
- From:Korean Journal of Urology
2002;43(1):62-66
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Some authors have suggested that erectile dysfunction correlates with the level of glycemic control and glycosylated hemoglobin can be used to predict erectile dysfunction in diabetic patients. This study evaluated whether or not glycosylated hemoglobin level can predict the effectiveness of sildenafil citrate, which is a first line therapy for erectile dysfunction. MATERIALS AND METHODS: A consecutive sample of 32 men with type 2 diabetes and erectile dysfunction completed the International Index of Erectile Function (IIEF) and had their glycosylated hemoglobin levels measured. 50mg of sildenafil citrate was prescribed at the first visit, which was then increased to 100mg if the symptom persisted. According to the response, the patients were divided into responders and nonresponders. The pretreatment clinical parameters (age, diabetic duration, erectile dysfunction duration, glycosylated hemoglobin level, body mass index, IIEF, diabetic complications, smoking, alcohol drinking) were recorded. The patients were divided into 3 groups according to the drug dosage (group 1 was 50mg responders, group 2 was 100mg responders, group 3 was nonresponders in any dosage) and the clinical parameters were compared and analyzed. RESULTS: The mean hemoglobin A1c level was 8.68 0.74% and 7.64 1.67% in the nonresponders and responders (p < 0.05), respectively. Diabetic neuropathy and diabetic retinopathy were significantly higher in the nonresponders (p < 0.05). The mean hemoglobin A1c levels of the three groups were 7.36 1.01, 7.78 0.98, and 8.64 0.44%, respectively and group 3 was significantly higher than the other groups (p < 0.05). CONCLUSIONS: High levels of glycosylated hemoglobin suggests a poor response to sildenafil citrate in diabetic patients with erectile dysfunction. Diabetic patients with neuropathy or retinopathy may have a low response for sildenafil citrate.
